Dr. Ian McNiece Appointed Biocardia Chief Scientific Officer
November 07, 2017
SAN CARLOS, Calif. –BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the appointment of Ian McNiece, PhD, as chief scientific officer of the company. Dr. McNiece has spent 30 years in both academic and commercial settings working in the areas of stem cell biology and clinical manufacturing for bone marrow transplantation and cellular therapy clinical applications.
Dr. McNiece has been a collaborator with BioCardia since 2007, directing manufacturing of stem cell products and clinical, manufacturing and control (CMC) development for several important clinical trials co-sponsored by the company, including TAC-HFT and POSEIDON.
Earlier in his career, he led development of cellular therapies at Amgen Inc. as laboratory head in the Department of Developmental Hematology, where he was also involved in the development of Filgrastim, Neulasta and Stemgen. Subsequently, he returned to academia and served as professor of medicine at several leading institutions, including MD Anderson Cancer Center (2012 to 2016), the University of Miami (2007 to 2012), Johns Hopkins University (2003 to 2007), and the University of Colorado Health Science Center (1997 to 2002).
Dr. McNiece received his PhD in Physiology from the University of Melbourne and performed his postdoctoral fellowship at the University of Virginia, Charlottesville.
“Ian has a tremendous pedigree and work ethic. He has been a valued collaborator for BioCardia as we undertook several important studies leading to our current Phase 3 CardiAMP study and our anticipated CardiALLO clinical study in heart failure,” said BioCardia CEO Peter Altman, PhD. “In his capacity as chief scientific officer, he will bring his expertise and leadership to our cell development and manufacturing team.”
BioCardia is the developer of the investigational CardiAMP therapy, which is designed to stimulate the body’s natural healing response. The therapy utilizes a personalized and minimally-invasive approach to the use of autologous bone marrow stem cells in the treatment of ischemic heart failure. Patients are screened for bone marrow characteristics that may result in a higher likelihood of their benefiting from the therapy. Likely responders are scheduled for therapy where they receive a high target dose of 200 million mononuclear cells directly to damaged regions of the heart using a delivery system that has been shown to result in superior cell delivery.
The company is currently conducting the CardiAMP Heart Failure Trial at up to 40 clinical centers in the United States. Patients interested in learning about the study can visit www.cardiamp.com or www.clinicaltrials.gov, Identifier NCT02438306, for more information.
BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. For more information, visit www.BioCardia.com
Forward Looking Statements
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans and overall market conditions. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 30, 2017 and amended on July 20, 2017, including under the caption titled “Risk Factors.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
David McClung, Vice President Finance & CFO
Michelle McAdam, Chronic Communications, Inc.
University of Minnesota
Saint Joseph Mercy
BioWorld Med Tech
BioWorld Med Tech
CALL US NOW
EMAIL US NOW